{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:49:10Z","timestamp":1775497750195,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10557-018-6843-5","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T09:09:06Z","timestamp":1547629746000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology"],"prefix":"10.1007","volume":"33","author":[{"given":"Krzysztof","family":"Oziera\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Balsam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Kap\u0142on-Cie\u015blicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Tymi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Peller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wancerz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Marchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Crespo-Leiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaros\u0142aw","family":"Dro\u017cd\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"6843_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"6843_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1067\/mhl.2002.126048","volume":"31","author":"TM Mueller","year":"2002","unstructured":"Mueller TM, Vuckovic KM, Knox DA, Williams RE. Telemanagement of heart failure: a diuretic treatment algorithm for advanced practice nurses. Heart Lung. 2002;31:340\u20137.","journal-title":"Heart Lung"},{"key":"6843_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.510","volume":"18","author":"M Komajda","year":"2016","unstructured":"Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514\u201322.","journal-title":"Eur J Heart Fail"},{"key":"6843_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173\u201384.","journal-title":"Eur J Heart Fail"},{"key":"6843_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"6843_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","volume":"4","author":"J Cosin","year":"2002","unstructured":"Cosin J, Diez J, investigators T. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507\u201313.","journal-title":"Eur J Heart Fail"},{"key":"6843_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0002-9343(01)00903-2","volume":"111","author":"MD Murray","year":"2001","unstructured":"Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513\u201320.","journal-title":"Am J Med"},{"key":"6843_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/01.HYP.34.1.138","volume":"34","author":"A Fortuno","year":"1999","unstructured":"Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34:138\u201343.","journal-title":"Hypertension"},{"key":"6843_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/FJC.0b013e3181a717f7","volume":"53","author":"K Harada","year":"2009","unstructured":"Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M, et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009;53:468\u201373.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6843_CR10","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","volume":"43","author":"B Lopez","year":"2004","unstructured":"Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"6843_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5603\/KP.a2015.0112","volume":"74","author":"P Balsam","year":"2016","unstructured":"Balsam P, Tyminska A, Kaplon-Cieslicka A, Ozieranski K, Peller M, Galas M, et al. Predictors of one-year outcome in patients hospitalised for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology. Kardiol Pol. 2016;74:9\u201317.","journal-title":"Kardiol Pol"},{"key":"6843_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.amjcard.2016.05.046","volume":"118","author":"A Kaplon-Cieslicka","year":"2016","unstructured":"Kaplon-Cieslicka A, Tyminska A, Peller M, Balsam P, Ozieranski K, Galas M, et al. Diagnosis, clinical course, and 1-year outcome in patients hospitalized for heart failure with preserved ejection fraction (from the Polish cohort of the European Society of Cardiology Heart Failure Long-Term Registry). Am J Cardiol. 2016;118:535\u201342.","journal-title":"Am J Cardiol"},{"key":"6843_CR13","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","volume":"97","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759\u201364.","journal-title":"Am J Cardiol"},{"key":"6843_CR14","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265\u201381.","journal-title":"Stat Med"},{"key":"6843_CR15","doi-asserted-by":"crossref","unstructured":"Austin PC, Jembere N, Chiu M. Propensity score matching and complex surveys. Stat Methods Med Res. 2018;27:1240\u201357.","DOI":"10.1177\/0962280216658920"},{"key":"6843_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.amjcard.2015.10.059","volume":"117","author":"RJ Mentz","year":"2016","unstructured":"Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, et al. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial). Am J Cardiol. 2016;117:404\u201311.","journal-title":"Am J Cardiol"},{"key":"6843_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1388-9842(03)00150-8","volume":"5","author":"K Muller","year":"2003","unstructured":"Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV\u2014efficacy and quality of life. Eur J Heart Fail. 2003;5:793\u2013801.","journal-title":"Eur J Heart Fail"},{"key":"6843_CR18","first-page":"273","volume":"2","author":"IS Anand","year":"1991","unstructured":"Anand IS, Kalra GS, Harris P, Poole-Wilson PA, Panzali A, De Giuli F, et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience. 1991;2:273\u20138.","journal-title":"Cardioscience"},{"key":"6843_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","volume":"20","author":"M Packer","year":"1992","unstructured":"Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"6843_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730\u20136.","journal-title":"Circulation"},{"key":"6843_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2165\/00002018-199614020-00005","volume":"14","author":"DC Brater","year":"1996","unstructured":"Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996;14:104\u201320.","journal-title":"Drug Saf"},{"key":"6843_CR22","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.4238\/2014.September.5.11","volume":"13","author":"LN Han","year":"2014","unstructured":"Han LN, Guo SL, Lin XM, Shi XM, Zang CB, Yang LM, et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res. 2014;13:7262\u201374.","journal-title":"Genet Mol Res"},{"key":"6843_CR23","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/ijcp.12144","volume":"67","author":"FL Dini","year":"2013","unstructured":"Dini FL, Ghio S, Klersy C, Rossi A, Simioniuc A, Scelsi L, et al. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract. 2013;67:656\u201364.","journal-title":"Int J Clin Pract"},{"key":"6843_CR24","doi-asserted-by":"crossref","unstructured":"Oziera\u0144ski K, Kap\u0142on-Cie\u015blicka A, Balsam P, Tymi\u0144ska A, Wancerz A, Peller M, et al. Do \u03b2-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry. Pol Arch Intern Med. 2018.","DOI":"10.20452\/pamw.4346"},{"key":"6843_CR25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/eurjhf\/hfr121","volume":"13","author":"MB Yilmaz","year":"2011","unstructured":"Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13:1244\u201352.","journal-title":"Eur J Heart Fail"},{"key":"6843_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0009-9236(95)90222-8","volume":"57","author":"DL Vargo","year":"1995","unstructured":"Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"6843_CR27","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.2147\/DDDT.S86300","volume":"9","author":"MR Ballester","year":"2015","unstructured":"Ballester MR, Roig E, Gich I, Puntes M, Delgadillo J, Santos B, et al. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. Drug Des Devel Ther. 2015;9:4291\u2013302.","journal-title":"Drug Des Devel Ther"},{"key":"6843_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1254\/fpj.118.97","volume":"118","author":"H Kido","year":"2001","unstructured":"Kido H, Ohtaki Y. Torasemide (LUPRAC): a review of its pharmacological and clinical profile. Nihon Yakurigaku Zasshi. 2001;118:97\u2013105.","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"6843_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jchf.2014.09.003","volume":"3","author":"RJ Mentz","year":"2015","unstructured":"Mentz RJ, Stevens SR, DeVore AD, Lala A, Vader JM, Abouezzeddine OF, et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015;3:97\u2013107.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"6843_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13063-016-1760-z","volume":"18","author":"P Balsam","year":"2017","unstructured":"Balsam P, Oziera\u0144ski K, Tymi\u0144ska A, G\u0142\u00f3wczy\u0144ska R, Peller M, Fojt A, et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure\u2014TORNADO: a study protocol for a randomized controlled trial. Trials. 2017;18(1):36.","journal-title":"Trials"},{"key":"6843_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.5603\/KP.2015.0051","volume":"73","author":"A Mamcarz","year":"2015","unstructured":"Mamcarz A, Filipiak KJ, Drozdz J, Nessler J, Tykarski A, Niemczyk M, et al. Loop diuretics: old and new ones\u2014which one to choose in clinical practice? Experts\u2019 group consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy and Working Group on Heart Failure. Kardiol Pol. 2015;73:225\u201332.","journal-title":"Kardiol Pol"},{"key":"6843_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","volume":"169","author":"J Buggey","year":"2015","unstructured":"Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169:323\u201333.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6843-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6843-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6843-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:17:42Z","timestamp":1579133862000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6843-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["6843"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6843-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"16 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}